Redeye initiates coverage of Elicera Therapeutics, a Swedish clinical-stage biotech company focusing...
Hansa delivers a healthy increase in patients using IDEFIRIX.
Q3e: sales of SEK 50m (up 10%), EBIT of SEK 1.5m (-2.
Redeye is happy to see that Railcare and LKAB have signed a 5-year agreement with a total value of ~...
Etteplan issued its second profit warning of the fiscal year prior to the Q3 report, citing ongoing ...
Sales growth of +7.8% and 20% EBIT margin in Q3e EBITDA '24e-'26e revised down 1.
Redeye takes a positive stance towards the partial divestment of Aspire.
Redeye provides a brief comment on Freemelt's order from a global orthopedic implant OEM, marking a ...
Redeye lowers its forecasts for Q3 and 2024 somewhat on the back of a slightly softer outlook in Nor...
Redeye offers a preview of Doro's Q3 results set to be released on October 25.
Minor estimate changes Gross margin improvements set to continue Trading at NTM EV/EBITA of ~10x Wh...
We trim '24e-'26e ARR by 1% on continued macro weakness Still awaiting a return in B2C business mome...
Solid Q3e with 7% organic growth and 22% EBITDA growth US market could be sluggish again, but focus ...
Efterfrågan har överlag hittills varit stabil, men med en svagare efterfrågan inom de breda industri...
Redeye has a positive view on the news from this morning, announcing that Saniona's collaboration wi...
